PD-1 drugs for Nasopharyngeal Carcinoma
4 tracked PD-1 drugs in the Nasopharyngeal Carcinoma race. The class explanation lives on the PD-1 page; the full indication pipeline across every mechanism is on the Nasopharyngeal Carcinoma page.
2 approved / phase 42 Phase 3
Head-to-head evidence: Camrelizumab vs Penpulimab · Camrelizumab vs Toripalimab · Penpulimab vs Tislelizumab · Penpulimab vs Toripalimab · Tislelizumab vs Toripalimab